• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Horizon Pharma Makes Another Bid for Depomed

Article

July 21, 2015.

Horizon Pharma (Dublin, Ireland) has again raised its offer to buy Depomed Inc (Newark, CA). Horizon is now offering $33 (£21.2) per share, contingent on the smaller drugmaker agreeing to start takeover talks, Reuters reports.   The equity value of the new offer works out to $1.97 billion, according to Thomson Reuters calculations. Horizon Pharma previously made an offer of $29.25 per share (about $1.74 billion) but Depomed refused to engage in talks. Horizon then raised its offer to $32.25 per share, which was again rejected earlier this week.   http://uk.reuters.com/article/2015/07/21/uk-depomed-m-a-horizon-phar-idUKKCN0PV19J20150721

Related Videos